ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study

Toni Choueiri reports on key results from ESMO Virtual Congress 2020 on 696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial

Produced by ESMO, https://oncologypro.esmo.org

Related content

Legal
Change cookie settings
Useful links
Get our news straight to your box

Subscribe to the ESMO Daily Reporter Alert and find out the latest advances in cancer care with our news and interviews to international experts. To receive the alert on a regular basis, create or login to your ESMO account and opt-in.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2025 European Society for Medical Oncology All rights reserved worldwide.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.